JP2020522502A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522502A5
JP2020522502A5 JP2019566327A JP2019566327A JP2020522502A5 JP 2020522502 A5 JP2020522502 A5 JP 2020522502A5 JP 2019566327 A JP2019566327 A JP 2019566327A JP 2019566327 A JP2019566327 A JP 2019566327A JP 2020522502 A5 JP2020522502 A5 JP 2020522502A5
Authority
JP
Japan
Prior art keywords
liquid formulation
liquid
preparation according
formulation
liquid preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566327A
Other languages
English (en)
Japanese (ja)
Other versions
JP7299166B2 (ja
JP2020522502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035473 external-priority patent/WO2018222922A1/en
Publication of JP2020522502A publication Critical patent/JP2020522502A/ja
Publication of JP2020522502A5 publication Critical patent/JP2020522502A5/ja
Priority to JP2023060542A priority Critical patent/JP7660603B2/ja
Application granted granted Critical
Publication of JP7299166B2 publication Critical patent/JP7299166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566327A 2017-06-02 2018-05-31 沈殿抵抗性低分子薬物製剤 Active JP7299166B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060542A JP7660603B2 (ja) 2017-06-02 2023-04-04 沈殿抵抗性低分子薬物製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514474P 2017-06-02 2017-06-02
US62/514,474 2017-06-02
PCT/US2018/035473 WO2018222922A1 (en) 2017-06-02 2018-05-31 Precipitation resistant small molecule drug formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060542A Division JP7660603B2 (ja) 2017-06-02 2023-04-04 沈殿抵抗性低分子薬物製剤

Publications (3)

Publication Number Publication Date
JP2020522502A JP2020522502A (ja) 2020-07-30
JP2020522502A5 true JP2020522502A5 (enExample) 2021-07-26
JP7299166B2 JP7299166B2 (ja) 2023-06-27

Family

ID=62705720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566327A Active JP7299166B2 (ja) 2017-06-02 2018-05-31 沈殿抵抗性低分子薬物製剤
JP2023060542A Active JP7660603B2 (ja) 2017-06-02 2023-04-04 沈殿抵抗性低分子薬物製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060542A Active JP7660603B2 (ja) 2017-06-02 2023-04-04 沈殿抵抗性低分子薬物製剤

Country Status (14)

Country Link
US (2) US11020403B2 (enExample)
EP (2) EP3630061B1 (enExample)
JP (2) JP7299166B2 (enExample)
KR (2) KR20240036128A (enExample)
CN (2) CN110709061B (enExample)
AU (2) AU2018275686B2 (enExample)
BR (1) BR112019024987A2 (enExample)
CO (1) CO2019013342A2 (enExample)
DK (1) DK3630061T3 (enExample)
ES (1) ES2982668T3 (enExample)
IL (1) IL270979A (enExample)
MX (1) MX2022012075A (enExample)
TW (1) TWI813571B (enExample)
WO (1) WO2018222922A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
EP3975993A1 (en) * 2019-05-31 2022-04-06 Xeris Pharmaceuticals, Inc. Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine
US20250025471A1 (en) * 2022-04-14 2025-01-23 Wisdom Pharmaceutical Co., Ltd Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection
US20240148678A1 (en) * 2022-10-19 2024-05-09 Xeris Pharmaceuticals, Inc. Sustained release injectable therapeutic formulations using aprotic polar solvents
EP4604922A1 (en) 2022-10-19 2025-08-27 Xeris Pharmaceuticals, Inc. Stable levothyroxine compositions in aprotic polar solvents

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016895A (en) 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
DE2905979C2 (de) * 1979-02-16 1981-01-22 Carl-Jacob Gatzen Verwendung von acetylierten, destillierten Monoglyceriden zur Behandlung von Fettstoffwechselstörungen beim Menschen
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
GB2119248A (en) 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
CH664005A5 (de) 1984-05-19 1988-01-29 Glatt Maschinen & Apparatebau Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens.
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4848094A (en) 1988-04-29 1989-07-18 Union Carbide Corporation Droplet freezing method and apparatus
US5031336A (en) 1989-08-31 1991-07-16 Abbott Laboratories Lyophilization of bulk pharmaceuticals
US5092843A (en) 1990-04-12 1992-03-03 Survival Technology, Inc. Dispersion multichamber auto-injector
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
AU7880991A (en) 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5208998A (en) 1991-02-25 1993-05-11 Oyler Jr James R Liquid substances freeze-drying systems and methods
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0625917B1 (fr) 1992-12-15 1998-03-25 Sanofi Dispositif pour la preparation d'une solution, d'une suspension ou d'une emulsion d'une substance medicinale
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
KR970705979A (ko) 1994-09-29 1997-11-03 디 히스 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles)
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5945128A (en) 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
JP2002512597A (ja) 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
AU5806998A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
DK0916347T3 (da) 1997-11-18 2003-04-22 Uni Pharma Kleon Tsetis A B E Farmaceutiske injicerbare opløsninger der indeholder paracetamol og kombinationer af paracetamol med andre aktive bestanddele
FR2783433B1 (fr) 1998-09-18 2001-02-16 Delab Seringues pour l'administration de formulations pateuses ou semi-solides
SE9803662D0 (sv) 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
DE19851777A1 (de) * 1998-11-10 2000-05-11 Basf Ag Verwendung von Estern oder Amiden hydroxylierter Carbonsäuren als Solubilisatoren
US6199297B1 (en) 1999-02-01 2001-03-13 Integrated Biosystems, Inc. Lyophilization apparatus and methods
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
WO2001078687A1 (en) 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN1283215C (zh) 2000-06-28 2006-11-08 A·J·舒克拉 生物活性物质的可生物降解载体和释放系统
CA2419067C (en) 2000-08-18 2008-12-23 Takeda Chemical Industries, Ltd. Injectable composition comprising benzimidazole compound and strong alkali
RO120121B1 (ro) 2000-12-18 2005-09-30 Elena Ionaşcu Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
WO2002070399A1 (en) 2001-03-06 2002-09-12 Texas Research International, Inc. A chemically and biologically resistant hydration system
DK1435945T3 (da) 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
JP4490095B2 (ja) 2001-06-29 2010-06-23 メドグラフト マイクロテック インコーポレイテッド 生体分解性の注入可能な移植物およびそれに関連する製造方法ならびに使用方法
EP1413310A1 (en) 2001-07-09 2004-04-28 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release compositions for injection and process for producing the same
US6733813B2 (en) 2001-08-02 2004-05-11 Ocean Spray Cranberries, Inc. Process for producing acids-enriched juice and acids-reduced juice
AU2002337692B2 (en) * 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
CA2466632C (en) 2001-11-14 2014-02-11 Alza Corporation Injectable depot compositions and uses thereof
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
CN1582170B (zh) 2001-12-18 2010-05-05 联合制药克伦茨蒂斯药物实验室公司 扑热息痛的肠胃外组合物
CN1171610C (zh) 2002-04-23 2004-10-20 张瑞香 一种治疗心脑血管和眼底病的中药针剂及其制备方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DE60327936D1 (de) 2002-10-17 2009-07-23 Univ British Columbia Modulatoren von ship-1
EP1558234B1 (en) 2002-10-25 2007-05-23 Dompé S.P.A. Painless injectable compositions containing salt of 2-arylpropionic acids
CN102205127A (zh) 2002-12-18 2011-10-05 阿尔乔医疗公司 类辣椒素的给药
CN1507858A (zh) 2002-12-19 2004-06-30 王玉万 含氟化氯霉素的兽用液体制剂
WO2004057959A2 (en) 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
WO2004098643A1 (en) 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
ES2298672T3 (es) 2003-04-14 2008-05-16 Wyeth Holdings Corporation Composiciones que contienen piperacilina y tazobactam utiles para inyeccion.
KR100517643B1 (ko) 2003-07-25 2005-09-28 한국과학기술연구원 온도 감응성 폴리포스파젠계 고분자, 이의 제조방법 및이를 이용한 주입형 온도 감응성 폴리포스파젠 하이드로젤
SI1502589T1 (sl) 2003-07-31 2006-12-31 Emdoka Bvba Drug Registration Veterinarske vodne injektibilne suspenzije, ki vsebujejo florfenikol
US20050100538A1 (en) 2003-07-31 2005-05-12 Attawia Mohamed Intradiscal injection of anti-oxidants
PL1658171T3 (pl) 2003-08-22 2008-10-31 Singulus Tech Ag Sposób łączenia substratów do wytwarzania dysków optycznych, oraz urządzenie do realizacji tego sposobu
AU2004267882A1 (en) * 2003-09-01 2005-03-10 Mayne Pharma International Pty Ltd Compositions and methods for delivery of biologically active agents
JP2007504256A (ja) * 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 生物活性剤の送達のための組成物及び方法
US20050069591A1 (en) 2003-09-30 2005-03-31 Howard Bernstein Injectable, oral, or topical sustained release pharmaceutical formulations
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
US20050240166A1 (en) 2004-04-26 2005-10-27 Microsolutions, Inc. Implantable device, formulation and method for anti-psychotic therapy using risperidone
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US20060160823A1 (en) 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
CN101056643A (zh) 2004-09-13 2007-10-17 Pr药品有限公司 雌二醇代谢物的长效可注射晶体制剂及其应用方法
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
DE602005008633D1 (de) * 2004-10-12 2008-09-11 Hoffmann La Roche Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen
JP5069130B2 (ja) 2005-01-27 2012-11-07 エリモス・ファーマスーティカルズ・エルエルシー Ndga化合物を包含するカテコールブタンの送達のための経口用製剤
EP1909824B1 (en) 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
EP1951248A4 (en) * 2005-11-14 2011-05-25 Peter D Winch NEW COLORED SOLUTIONS OF INJECTABLE MEDICINAL PRODUCTS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
AU2007207618B2 (en) 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP2001439A2 (en) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
CA2648243C (en) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20090143737A1 (en) 2006-05-17 2009-06-04 Terumo Kabushiki Kaisha, Indwelling needle assembly
US20070275030A1 (en) 2006-05-25 2007-11-29 The General Hospital Corporation Dba Massachusetts General Hospital Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
CA2662827C (en) 2006-09-07 2015-04-07 Merial Limited Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
CA2665101A1 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
WO2008098212A2 (en) 2007-02-08 2008-08-14 Diobex, Inc. Extended release formulations of glucagon and other peptides and proteins
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー/エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2152243A2 (en) 2007-04-30 2010-02-17 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
ES2529648T3 (es) * 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
EP2030610A1 (en) * 2007-08-31 2009-03-04 Archimedes Development Limited Non-aqueous pharmaceutical compositions
TW200922635A (en) 2007-08-31 2009-06-01 Archimedes Dev Ltd Non-aqueous pharmaceutical compositions
MX2010001911A (es) * 2007-08-31 2010-05-13 Archimedes Dev Ltd Composiciones farmaceuticas no acuosas.
US20090088393A1 (en) 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
CN101877963A (zh) 2007-11-28 2010-11-03 泰华制药工业有限公司 延缓临床确诊的多发性硬化症发作的方法
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
MX2011000795A (es) 2008-07-23 2011-03-29 Bharat Serums & Vaccines Ltd Nanoemulsion estable inyectable de docetaxel de aceite en agua.
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
JP5618440B2 (ja) 2008-08-25 2014-11-05 電気化学工業株式会社 注射器
WO2010036702A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110118578A1 (en) 2009-11-17 2011-05-19 Roche Diagnostics Operations, Inc. Hypoglycemic treatment methods and systems
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
JP5632226B2 (ja) 2010-07-30 2014-11-26 株式会社細川洋行 医療用多層チューブ、および医療用輸液バッグ
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
EP2691100A4 (en) * 2011-03-31 2014-09-24 Acorda Therapeutics Inc INTRANASAL PHARMACEUTICAL BENZODIAZEPINE COMPOSITIONS
DK3415139T3 (da) * 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
ES2574761T3 (es) 2011-10-31 2016-06-21 Xeris Pharmaceuticals, Inc. Formulaciones para el tratamiento de la diabetes
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
AU2013308693A1 (en) 2012-08-29 2015-03-12 Mannkind Corporation Method and composition for treating hyperglycemia
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160000702A1 (en) * 2013-02-22 2016-01-07 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines
US20160000803A1 (en) * 2013-02-22 2016-01-07 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal administration of benzodiazepines
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN104706589A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种地西泮药物组合物、其制备方法及用途
EP3102184B1 (en) 2014-02-06 2019-01-30 Xeris Pharmaceuticals, Inc. Stable peptide formulations and methods for preparation
WO2015153728A1 (en) 2014-04-02 2015-10-08 Xeris Pharmaceuticals, Inc. Polar aprotic solvent-compatible infusion sets, components, and methods
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
EP3307295A1 (en) 2015-06-10 2018-04-18 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação

Similar Documents

Publication Publication Date Title
RU2144356C1 (ru) Композиция для инъекций на основе таксоидов
CN1041793C (zh) 氟化氯霉素药物组合物
ES2624442T3 (es) Composiciones farmacéuticas de Pemetrexed
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
IL275388B2 (en) Liquid protein formulations containing viscosity reducing agents
WO2009111057A4 (en) Fulvestrant formulations
CA2609242A1 (en) Injectable compositions and process for preparation of such compositions
WO2016059592A1 (en) Stable injectable composition of peptide drugs and process for its preparation
JP2019537589A5 (enExample)
CN110709061A (zh) 抗沉淀的小分子药物制剂
EP2205215A2 (en) Docetaxel injectable composition, being absolutely free of ethanol
JP2020505429A5 (enExample)
JP2007515425A (ja) 医薬組成物
JP2014502282A (ja) 安定な使用準備済みセトロレリックス注射液
JP2015520762A5 (enExample)
ES2315942T3 (es) Composicion veterinaria inyectable que contiene florfenicol.
JPS605567B2 (ja) オキシテトラサイクリンの調合液
ZA200306391B (en) Suspension of ceftiofur hydrochloride.
JP5217136B2 (ja) 直腸、尿道および膣適用用半固形状製剤。
KR100548948B1 (ko) 플로르페니콜의 약제학적 조성물
CA3143663A1 (en) A stable formulation of cetrorelix
KR940000066B1 (ko) 약제학적 제제
WO2022269572A1 (en) Pharmaceutical compositions
CN101155584A (zh) 给药伊沙匹隆的方法
BRPI0621841B1 (pt) formulação líquida